Alert

Recommended Alerts

Sign Up For Alerts

Drug Pricing: What Happened in 2019 and What to Watch in 2020

Have you heard that drug prices are too high? If not, you have not been listening to President Donald Trump, Secretary of Health and Human Services (“HHS”) Alex Azar, or almost any member of Congress. In the past year, a dizzying array of drug pricing actions and proposals have come out of the White House and Congress, as well as the governor’s offices and legislative halls in most states.

Read More

President Signs Law Reauthorizing Drug and Device User Fees: Legislation Contains Several Important FDA Reforms

Practices: Life Sciences, FDA Regulatory, Advertising & Promotion, Congressional Investigations & Public Policy, Due Diligence Reviews & Transactional Support, FDA Enforcement Actions & Litigation, Post-Approval Compliance, Regulatory Strategy, Product Development & Product Approvals

Printer-Friendly Version

Cookie Settings